|
|
2006
New Treatments for Hepatitis C
… maybe
October 2006
October 27, 2003
Hep C drug starts Phase II testing
USA-based biopharmaceutical company
ViroPharma says that it has begun patient dosing in a Phase II trial of
HCV-796, its orally-active hepatitis C virus (HCV) polymerase inhibitor.
...
New Data for Investigational Hepatitis C
Drug Telaprevir (VX-950 ...
Forestier of Saarland University Hospital
in Homburg, Germany will review the current status of 20 ... of
developing chronic liver disease, cirrhosis, liver cancer and early
death. About Vertex Vertex Pharmaceuticals ...
New Data for Investigational Hepatitis C
Drug Telaprevir (VX-950 ...
Researchers will present new data this
week suggesting that both wild-type hepatitis C virus and res...
Schering-Plough Touts Ongoing Hep-C Data
Houston
Chronicle - United States
... said an ongoing study of its
hepatitis C treatment showed sustained viral suppression in 56 percent
of patients after nearly a year on the drug. ...
Vertex reports mixed results for hepatitis C
drug
Reuters -
USA
... (VRTX.O: Quote, Profile,
Research) on Friday said some patients in early-stage trials of its
experimental treatment for hepatitis C virus continued to have the ...
New Data for Investigational Hepatitis C
Drug Telaprevir (VX-950) ...
Yahoo! News (press
release) - USA
27 /PRNewswire-FirstCall/ --
Researchers will present new data this week suggesting that both
wild-type hepatitis C virus and resistant variants were ...
Major Breakthrough in Treating Hepatitis C
Announced
Researchers from Scripps Institute and La
Jolla Institute for Allergy and Immunology have come to the same
conclusion: altering a specific immune system molecule allows a rat to
successfully fight Hepatitis C. ...
IDENIX PHARMA TEAMS WITH METABASIS TO
ENHANCE HEPATITIS C PIPELINE
Idenix Pharmaceuticals, Inc. announced a
two-year research collaboration agreement with Metabasis Therapeutics,
Inc.
[Case reports] Hepatic angiomyolipoma with
trace amounts of fat: a ...
By Wang,
S-N, Tsai, K-B, Lee, K-T
In this case, the viral hepatitis
markers, including hepatitis B antigen and anti-hepatitis C virus
antibody, were negative. The serum -fetoprotein level was 3.4 ng/ml and
in the normal range. Abdominal ultrasonography showed a ...
Roche Oral Polymerase Inhibitor R1626 Shows
Strong Antiviral ...
By Roche
BOSTON--(HSMN NewsFeed)--New
clinical data on the hepatitis C polymerase inhibitor R1626 - currently
in development by Roche - show viral reductions greater than those ...
Biopharmaceuticals Roche , R1626, polymerase inhibitor, Hepatitis C.
October 26, 2006
Idenix Pharmaceuticals Announces Strategic
Collaboration To ...
Earthtimes.org - USA
... anti-HCV drug candidates that
could be complementary to valopicitabine, our lead drug candidate being
developed for the treatment of hepatitis C, through an ...
Idenix Pharma Teams With Metabasis To
Enhance Hepatitis C Pipeline ...
Trading Markets - Los
Angeles,CA,USA
... technology will be applied to
proprietary Idenix compounds to develop second-generation nucleoside
analog drug candidates for the treatment of hepatitis C. ...
October 24, 2006
Schering-Plough Highlights Hepatitis C
Clinical Data Presentations ...
Earthtimes.org - USA
Among the key presentations will
be data from the EPIC3 (Evaluation of PEG-INTRON in Control of Hepatitis
C Cirrhosis) study, a large, prospective, controlled ...
InterMune to Present Research on ITMN-191 in
Hepatitis C at Two ...
Earthtimes.org - USA
InterMune has successfully
completed preclinical toxicology and pharmacokinetic studies in multiple
species in support of initiating Phase I clinical studies ...
Peregrine Completes Patient Enrollment in
Phase Ib Bavituximab ...
PR Newswire (press
release) - New York,NY,USA
... (Nasdaq: PPHM), a
biopharmaceutical company developing targeted therapeutics for the
treatment of cancer and hepatitis C virus (HCV) infection, today
reported ...
October 17, 2006
Hepatitis drug from Vertex could reap
billions
CNNMoney.com - USA
... Vertex (down $0.58 to $36.19,
Charts), a biotech based in Cambridge, Mass., is experimenting with a
potential blockbuster hepatitis C treatment called VX-950. ...
GlobeImmune Announces GI-5005 Tarmogen Data
for Chronic Hepatitis
Market Wire
(press release) - USA
announced today that the interim results
from a placebo-controlled Phase 1b study of GI-5005 in patients
chronically
infected with hepatitis C virus will be ...
October 16, 2006
Human Genome Sciences Reports Positive Interim Quality-of-Life …
PharmaLive.com (press release) – Newtown, PA, USA
… safety and impact on health-related quality of life of Albuferon™ in combination with ribavirin in patients with genotype 1 chronic hepatitis C (HCV) who …
October 13, 2006
Roche Progresses its Oral Polymerase Inhibitor Ito Phase II …
Earthtimes - USA
… start of the first phase II development study to evaluate R1626, their promising inhibitor, for the treatment of hepatitis C. The investigational drug …
October 12, 2006
Tacere Therapeutics gets seed funding for hepatitis C treatment
San Jose Business Journal – CA, USA
… from Japan’s Hokkaido Venture Capital to establish operations and perform preclinical development of its lead candidate for the treatment of hepatitis C.…
October 9, 2006
La Jolla Institute touts hepatitis C breakthrough
San Diego Daily Transcript (subscription) – San Diego, CA, USA
… & Immunology announced what it called a “major finding” Monday that the organization said could lead to a new approach for treating hepatitis C and other …
October 5, 2006
Hep C virus core protein induces interleukin production in …
Therapeutics Daily
(subscription) (press release) - Newtown, PA, USA
A study from the United States has
reported on the induction of interleukin-6 (IL-6) by hepatitis C virus
(HCV) core protein in hepatitis C-associated mixed ...
October 4, 2006
AVI BioPharma says dosage levels on hepatitis C drug ineffective
Reuters USA
AVI BioPharma Inc. said its drug candidate for the hepatitis C virus infection did not …
October 5, 2006
Human Genome Sciences tests Hep C drug
United Press International - USA
ROCKVILLE, Md., Oct. 4 (UPI) – US firm Human Genome Sciences said Wednesday it has begun a phase 3 trial of Albuferon in patients with chronic hepatitis C. …
September 2006
September 28, 2006
Novelos Therapeutics Enrolls 1st Patient in Hepatitis C Trial with …
PharmaLive.com (press release) – Newton, PA, USA
… focused on the development of therapeutics to treat cancer and hepatitis, today announced that the first patient has been enrolled in a hepatitis C trial with …
September 21, 2006
Tripep reports positive data for hepatitis C DNA vaccine using …
Therapeutics Daily (subscription) (press release) – Newtown, PA, USA
… results showing its ChronVac-C DNA vaccine using Inovio’s MedPulser DNA delivery system produced a strong immune response against hepatitis C virus (HCV) in a …
September 14, 2006
Chronic hepatitis C infection may be modulated by combination …
Therapeutics Daily (subscription) (press release) – Newtown, PA, USA
... ribavirin treatment on nuclear-factor kB (NF-kappa B), transforming growth factor beta-1 (TGF-beta 1), and metalloproteinase activity in chronic hepatitis C. ...
Hepatitis C virus gene expression involves multidrug resistance ...
Therapeutics Daily (subscription) (press release) – Newtown, PA, USA
… nuclear factor (HNF) 1 and hepatocyte nuclear factor (HNF) 4 mediate hepatic multidrug resistance protein (MRP) 2 upregulation during hepatitis C virus (HCV …
Near Full-Length Hepatitis C Virus Genome Cloned from Clinical …
Therapeutics Daily (subscription) (press release) – Newtown, PA, USA & NewsRX.com
A study from the United States has reported that near full-length hepatitis C virus (HCV) genome can be cloned from clinical samples …
September 12, 2006
UPDATE 1-Valeant hepatitis C drug misses efficacy goal
Reuters - USA
Valeant Pharmaceuticals International (VRX.N: Quote, Profile, Research) on Tuesday said its chronic hepatitis C drug Viramidine failed to …
September 8, 2006
Bioenvision’s Suvus™ Lowers Viral Load in Chronic Hepatitis C …
Genetic Engineering News (press release) – Larchmont, NY, USA
(NasdaqGM:BIVN) today announced results of a randomized Phase II trial of Suvus™ in patients with chronic hepatitis C virus infection (HCV) …
|
Hey ... I'm not a doctor - don't even play one on t.v. - so, check out my little disclaimer ... here.
We're
damn proud to tell ya that
website by
Nerd Grrl Design
questions? comments?
Hep C Straightup
respects your right to
PRIVACY
please click on
the webmaster (also a hepper, by the
way)
Hep C Straightup
- Copyright
Ó 2008. All
Rights Reserved.
|
on:
08.15.2008 
